Investor Presentation December 2025 Cautionary Statements Forward-Looking Statements: This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from these statements. Forward-looking statements are often identified by words like "will," "may," "could," "should," " ...

Financial Highlights - RELX achieved underlying revenue growth of +7%[7, 10] - The company saw underlying adjusted operating profit growth of +9%[7, 11] - Adjusted EPS growth at constant currency was +10%[7, 11] - Full year dividend growth was +7%[7] - Revenue reached £94 billion[8] - Adjusted operating profit was £32 billion[8] Segment Performance (H1 2025 Underlying Revenue Growth) - Risk segment grew by +8%[35] - Scientific, Technical & Medical (STM) segment grew by +5%[35] - Legal segment grew by +9%[35] - Exhibitions segment grew by +8%[35] Revenue Breakdown (H1 2025) - Electronic format accounted for 84% of revenue[15] - Subscription-based revenue made up 54% of the total[15] - North America contributed 60% of the revenue[15] Strategic Direction - RELX focuses on developing sophisticated information-based analytics and decision tools[20] - The company prioritizes organic growth, supplemented by targeted acquisitions[20]

Energy Demand and Inflows - System gross demand is expected to grow by 1.7% from 2024 to 2025[22] - The Compound Annual Growth Rate (CAGR) for gross demand over the last 5 years is 4.1%[23] - Natural energy inflow in October 2025 was 67% of the Long-Term Average (LTA), with November 2025 recovering to 75% LTA[27] - The expected natural energy inflow for 2025 is 79.6% of the LTA[27] - From 2016 to 2025, the average inflow was 84% LTA, the lowest in history[33] Generation and Storage - Peak storage level for 2025 reached 70%, similar to 2024, with a minimum expected storage of 44% by 2025[36] - Distributed Generation (DG) is developing faster than centralized solar generation[39] Spot Prices and Market Prices - Average spot price in the Southeast region since January 1st is 219 BRL/MWh[44, 51] - Average spot price in the Northeast region since January 1st is 167 BRL/MWh[44, 51] Curtailment - Wind curtailment reached 39.9% for some producers, averaged from December 2024 to November 2025[59] - Solar curtailment reached 44.8% for some producers, averaged from December 2024 to November 2025[61] - The industry's current curtailment forecast is more negative, anticipating an average of 20% to 25%[70] TAG (Gas Transportation) - Market opening has led to a 2,660% increase in the number of contracts and a 106% increase in active chargers among the three main carriers between 2022 and 2025[93] - Market opening brought new gas suppliers, with 71% of the volume contracted by distributors in the Northeast Region in 2024 coming from private suppliers[99] - Relative savings in TAG's area due to market opening is R$7 billion[99]

Financial Performance - Total net revenues reached RMB3,208.3 million[17] in 2025Q3, compared to RMB1,444 million[52] in 2023Q3 and RMB3,541 million[52] in 2024Q3 - Non-GAAP net income was RMB502.8 million[18] in 2025Q3, versus RMB306 million[55] in 2023Q3 and RMB503 million[55] in 2024Q3 - As of September 30, 2025, cash and cash equivalents, restricted cash, and time deposits amounted to RMB9,142 million[74] - Net cash provided by operating activities for the three months ended September 30, 2025, was RMB456 million[74] Store Expansion - The company's global teahouse footprint reached 7,338 teahouses[19] by the end of 2025Q3 - There was a net increase of 300 teahouses[19] (QoQ) - Teahouses in Greater China increased by 246[23] (QoQ), while those outside Greater China increased by 54[23] (QoQ) - Expansion included new markets, with 8 teahouses in Vietnam[23] and 3 in the Philippines[23] Customer Engagement - Cumulative registered members reached 222.0 million[37] as of September 30, 2025, representing a 36.7%[36] YoY increase and a 15.0 million[36] net increase QoQ - Third-party delivery platform GMV mix was 57.8%[36] for the three months ended September 30, 2025 Revenue Breakdown - In 2025Q3, franchised teahouses contributed RMB2,812 million[65] to total net revenues, while company-owned teahouses contributed RMB397 million[65]

Transaction Overview - Allwyn and OPAP are combining to unlock long-term value for OPAP shareholders, positioning them to benefit from industry trends and mitigate risks[22, 27] - The transaction aims to create the second largest listed lottery and gaming operator globally, with greater scale to seize opportunities[32] - The combined company is expected to have a pro forma LTM H1-25 Adjusted EBITDA of €1.9 billion, including PrizePicks and Novibet[28, 33] - The transaction is expected to be double-digit accretive in the first year post completion[28] Financial Highlights - Allwyn's pro forma Adjusted EBITDA margin is 37% of pro forma Net Revenue[50] - Allwyn's pro forma online NGR is 55%[50] - Allwyn has a strong track record of growth, with Net Revenue, Adjusted EBITDA, and Adjusted EBITDA – Capex all more than doubling since 2019[59] - Allwyn has distributed over €3.3 billion in capital to its and OPAP's shareholders since 2019[253] Growth Strategy - Allwyn has multiple organic and inorganic growth levers, including PrizePicks, IWG, and Betano[37] - Allwyn's medium-term growth will be driven by high-growth, market-leading assets, representing ~30% of pro forma LTM H1-25 Adjusted EBITDA[39] - The combined company will be highly diversified geographically and by product, with 57% of pro forma LTM H1-25 NGR from exclusive revenue[41]

Sustainability Management & Value Creation - Daiichi Sankyo defines sustainability management as contributing to the sustainable development of society through innovative pharmaceutical products [19] - Three key elements drive Daiichi Sankyo's value creation: Science & Technology, Human Resources, and Patient Centricity [20] - The company aims to enhance corporate value by strengthening human and intellectual capital [8] - Daiichi Sankyo is integrating sustainability initiatives based on double materiality into the 6th Medium-Term Business Plan [92] Human Capital & Innovation - Daiichi Sankyo is strengthening Science & Technology talent through recruitment, reskilling programs, and investments in research facilities [23, 25] - The company is driving company-wide transformation through advanced digital technologies with Project 4D [25] - Innovation, robust pipelines, and global challenge opportunities fuel the continuous attraction and development of top talent [27] Patient Centricity - Daiichi Sankyo is embedding Patient Centricity across the group through internal communications, training programs, and engagement with patient groups [37, 65] - The company is promoting patient-focused drug development (PFDD) to incorporate patient voices into the drug development process [66] - Daiichi Sankyo collaborates globally with over 900 patient advocacy groups annually [66] - Daiichi Sankyo Brazil (DSBR) and American Regent (ARI) collaborated to deliver antidotes to Brazil within four days to support patients with poisoning symptoms [44]

BlueScope Overview - BlueScope aims for an annual EBIT uplift of approximately $500 million by 2030 through growth initiatives and investments[16] - BlueScope has returned over $3.8 billion in dividends and buy-backs since FY2017[16] - BlueScope is positioning its 1,250ha property portfolio for strategic value realization[22] - BlueScope expects $179 million net proceeds after taxes and fees from sale of 50% stake in Tata BlueScope Steel (TBSL)[20] New Zealand and Pacific Islands (NZPI) Segment - The EAF project is expected to reduce NZ Steel's Scope 1 and 2 greenhouse gas emissions by up to one million tonnes, or approximately 55%[38] - The EAF project would have indicatively improved FY2025 EBIT by approximately $80 million if operational[39] - Construction segment accounts for approximately 70% of NZPI's end-use segments[49] - COLORSTEEL sales volume has grown at a CAGR of 5% indexed at FY2016[63] Climate and Sustainability - BlueScope has a 12% intensity reduction target for steelmaking GHG emissions since FY2018[179] - BlueScope has a 30% intensity reduction target for non-steelmaking GHG emissions since FY2018[179] - BlueScope estimates projects are estimated to take steelmaking emissions intensity below 1.3 tCO2-e per tonne by 2030[184] - BlueScope has completed 192 team-based HSE risk control improvement projects in FY2025[147]

Financial Performance and Targets - Hydro achieved an adjusted RoaCE of 13.5% over the last 5 years [13, 183] - The company aims to deliver NOK 6.5 billion in annual improvements by 2030 through its improvement program [188, 246] - Hydro's capital allocation targets for 2025 and 2026 are reduced to NOK 13.5 billion [249] - The company targets an adjusted net debt to adjusted EBITDA ratio well below 2.0x over the cycle, with the LTM Q3-2025 ratio at 0.7x [186] - Total shareholder distributions since 2021 amount to NOK 41.0 billion [186] Extrusion Business - Hydro Extrusions is targeting an EBITDA uplift of NOK 8.0 - 10.0 billion by 2030 [68] - The company intends to reduce extrusion capacity by approximately 80 kt annually in Europe [134] - Hydro Building Systems experienced a 54% increase in EBITDA YTD 2025 in the Middle East [159] Recycling Business - The company estimates EUR 9 million out of EUR 10-15 million of Alumetal synergies will be delivered in 2025 [80] - Hydro is targeting an extrusion ingot recycling EBITDA margin of approximately USD 95/tonne in Q3 2025 [72] - Recycling adjusted EBITDA roadmap 2030 potential is NOK ~ 5 - 6 billion [83] Low-Carbon Transition and Sustainability - Hydro is projecting to deliver a CO2 reduction of 15% by year-end 2025 [14] - The company has a target to reduce CO2 emissions by 30% by 2030 [92] - Hydro has secured a new long-term power contract with Hafslund Kraft AS for 3.5 TWh of renewable energy supply from 2031 to 2040 [90]

Chugai's Value Creation & Sustainability - Chugai reorganized its value creation process in 2024, using materiality as axes, aiming to realize advanced and sustainable patient-centric healthcare[9] - The company focuses on creating innovative drugs and services, providing individualized solutions, ensuring quality, and co-creating a healthcare ecosystem[12] - Chugai is implementing materiality by aligning business activities with its materiality story, reflected in management strategies and division activities[14, 16, 20] - A project using the antibody drug discovery support technology MALEXA has advanced to clinical development stage[22, 23] - The company is constructing a disease database for blood coagulation disorders in cooperation with patient associations and academia[29, 35] - Chugai achieved 100% renewable energy ratio in purchased electricity[39] Mid-Size Molecule Drug Platform - Chugai is establishing a pharmaceutical technology platform for mid-size molecule drugs to provide new treatment options[6, 52] - The company is developing a new liquid-phase synthesis method to improve the efficiency of producing mid-size molecules[65] - Through joint research, the cost of certain non-natural amino acids was reduced to less than one third[77] - A 55.5 billion yen investment was made in Fujieda in 2024, 128.8 billion yen in Yokohama in 2022, and 4.5 billion yen in Ukima in 2020[90] Governance and Shareholder Value - Chugai emphasizes dialogue with investors to enhance governance and increase shareholder value[120] - Non-executive directors play a key role in monitoring and advising on management from a global perspective[129] - The company's average annual Total Shareholder Return (TSR) for the past 10 years is 23.5%, compared to 9.5% for TOPIX and 7.8% for TOPIX-17 Pharmaceutical Index[150]

Immutep Overview - Immutep has approximately A$109.85 million in cash and cash equivalents, providing a runway to the end of CY2026[14] - Immutep is developing four clinical-stage assets, including eftilagimod alfa (efti) and IMP761, designed to empower the immune system to fight cancer and autoimmune diseases[14] TACTI-004 (KEYNOTE-F91) Phase III Trial - The NSCLC drug market is expected to reach US$48 billion in sales in 2031[14,24] - The TACTI-004 Phase III trial has activated over 100 clinical sites across 24 countries and enrolled over 170 patients as of October 2025[25,30] - MSD is supplying KEYTRUDA for the TACTI-004 trial, with a typical ICI supply value of approximately US$100 million[30,32] Efficacy and Safety - In the INSIGHT-003 trial, a 62.7% objective response rate and a 90.2% disease control rate were observed across all PD-L1 expression levels in first-line NSCLC patients[52] - The EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint, demonstrating a median 51.5% tumor hyalinization/fibrosis rate (p<0.001) with neoadjuvant efti + KEYTRUDA + radiotherapy[52,70] Financials - Immutep's total revenue and other income were A$10.3 million in FY25, compared to A$7.8 million in FY24[79,80] - Research and development and intellectual property expenses increased to A$61.4 million in FY25[79,80] - The company reported a net loss of A$61.4 million in FY25[79] Intellectual Property - In FY24, seven patents were granted for efti, including six patents for efti in combination with a PD-1 pathway inhibitor[84] - Seven patents were granted for IMP761 in FY24[84] Anti-PD-(L)1 Therapies Sales - KEYTRUDA sales were approximately $29.5 billion in 2024[50,51] - OPDIVO sales were approximately $9.3 billion in 2024[50,51]